Amexdrug Corp. (AXRX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
369 SOUTH DOHENY DR SUITE 326 BEVERLY HILLS, CA 90211 |
| State of Incorp. | CA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 5122 - Drugs, Drug Proprietaries, and Druggists' Sundries (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2012 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets | |||
| Cash, cash equivalents, and short-term investments | |||
| Cash and cash equivalents | |||
| Short-term investments | |||
| Receivables | |||
| Inventory, net of allowances, customer advances and progress billings | |||
| Inventory | |||
| Prepaid expense and other current assets | |||
| Other undisclosed current assets | |||
| Total current assets: | |||
| Noncurrent Assets | |||
| Property, plant and equipment | |||
| Intangible assets, net (including goodwill) | |||
| Goodwill | |||
| Deposits noncurrent assets | |||
| Other undisclosed noncurrent assets | |||
| Total noncurrent assets: | |||
| Other undisclosed assets | |||
| TOTAL ASSETS: | |||
| LIABILITIES AND EQUITY | |||
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | |||
| Accounts payable | |||
| Accrued liabilities | |||
| Debt | |||
| Other undisclosed current liabilities | |||
| Total current liabilities: | |||
| Noncurrent Liabilities | |||
| Long-term debt and lease obligation | |||
| Long-term debt, excluding current maturities | |||
| Total noncurrent liabilities: | |||
| Total liabilities: | |||
| Equity | |||
| Equity, attributable to parent | |||
| Common stock | |||
| Treasury stock, value | |||
| Additional paid in capital | |||
| Retained earnings | |||
| Total equity: | |||
| TOTAL LIABILITIES AND EQUITY: | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2012 | ||
|---|---|---|
| Revenues | ||
| Cost of revenue | ||
| Cost of goods and services sold | ||
| Other undisclosed gross profit | ||
| Gross profit: | ||
| Operating expenses | ||
| Other undisclosed operating loss | ||
| Operating income: | ||
| Nonoperating expense | ||
| Other nonoperating expense | ||
| Interest and debt expense | ||
| Income from continuing operations before equity method investments, income taxes: | ||
| Other undisclosed loss from continuing operations before income taxes | ||
| Income from continuing operations before income taxes: | ||
| Income tax expense | ||
| Income from continuing operations: | ||
| Income before gain (loss) on sale of properties: | ||
| Net income available to common stockholders, diluted: | ||
Comprehensive Income ($ in thousands)
| 12/31/2012 | ||
|---|---|---|
| Net income: | ||
| Comprehensive income, net of tax, attributable to parent: | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.